Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Anti-Cancer Drugs is Scopus-indexed (Q2, CiteScore 4.6), WoS SCIE. It is covered by India's One Nation One Subscription scheme for reading access. Published by Lippincott Williams and Wilkins.
Checked against the index lists dated .
ISSN 0959-4973Verify ISSN ↗1473-5741Verify ISSN ↗
Publisher: Lippincott Williams and Wilkins
Cost to publish: No APC data — check the publisher
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Pharmacology (medical) | 113 / 278 | 59th | Q2 |
| Oncology | 181 / 428 | 57th | Q2 |
| Pharmacology | 163 / 328 | 50th | Q2 |
| Cancer Research | 144 / 233 | 38th | Q3 |
Not listed in: DOAJ, ABDC, ABS / AJG, FT50, UT Dallas, ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 1990–present, best quartile Q2, CiteScore 4.6.
Anti-Cancer Drugs is Q2 in Pharmacology (medical) (rank 113 of 278), Q2 in Oncology (rank 181 of 428) and Q2 in Pharmacology (rank 163 of 328), by CiteScore 2025. It is ranked in 4 subject areas in all.
Anti-Cancer Drugs is indexed in the Science Citation Index Expanded, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 4.6, which places it in quartile Q2 at the 59th percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.506, quartile Q3, with an H-index of 106.
Anti-Cancer Drugs is published by Lippincott Williams and Wilkins. Its print ISSN is 0959-4973 and its online ISSN is 1473-5741.
Yes. It is part of the One Nation One Subscription (ONOS) national subscription, so readers at participating Indian institutions get its full text. ONOS does not cover its article processing charge.
Yes — indexed in the Science Citation Index Expanded.
No — it is not registered as an open-access journal in DOAJ or Scopus.
Anti-Cancer Drugs has an h-index of 115 and a 2-year mean of 2.09 citations per paper (OpenAlex). Its Scopus CiteScore is 4.6, quartile Q2. On 2-year citations it ranks #125 of 271 Scopus journals in Pharmacology (medical).
Anti-Cancer Drugs published 120 papers in 2025; its busiest recent year was 2021 with 239. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 99 research articles (2025–2026), authors are most often from China (65%), United States (8.1%) and Türkiye (6.4%). More than half of recent authorship comes from one country.
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 10 retracted papers are recorded (2 per 1,000 papers). The Problematic Paper Screener flags none of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.